Updates - Page 4
Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications
These include the first oligonucleotide-based therapies (Spinraza, Exondys, Vyondys), in vivo gene therapies (Luxturna and Zolgensma) and the first cell therapies (Kymriah, Yescarta, Tescartus). Such novel therapeutics treat disorders varying…
Read update
Lung epithelium in vitro modelling of SARS-CoV2 infections to aid Covid-19 treatments
Newcells Biotech’s team has developed a state-of-the-art iPSC-derived in vitro model of the human upper airway to accelerate the development of novel treatments against Covid-19 and other respiratory…
Read update
Global scientific expertise built into every NB product & service
At Newcells Biotech, we build our Industry leading scientific expertise and technical excellence into all the products and services we offer to our customers, delivering innovative solutions for drug…
Read update
NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study
Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…
Read update
Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing
Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded
Read update
Our commitment to the 3Rs
There are few topics more controversial than the use of animals in science, despite the enormous contribution animal experimentation continues to make to the development of new medicines and…
Read update
Newcells Biotech secures over £5m for 3D tissue models
Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.The funding…
Read update
Developing a 3D in vitro proximal tubule model for chronic toxicity studies
The kidney proximal tubule is of key interest in drug discovery. This is due to its primary role in the excretion and reabsorption of xenobiotics, such as drugs and…
Read update
Covid-19 action plan – 2021 update
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and…
Read update
Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges
The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the…
Read update
Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we…
Read update
Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids
At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which…
Read update
